OmniAb Appoints Amechi Nwachuku as Chief Operating Officer to Accelerate Growth of xPloration® Single B-Cell Screening Platform
OmniAb, Inc., a biotechnology company recognized for its advanced antibody discovery technologies that support the development of next-generation therapeutics, has announced the appointment of Amechi Nwachuku as Executive Vice President and Chief Operating Officer. The newly created executive role became effective immediately and reflects the company’s strategic focus on expanding the commercial reach and operational capabilities of its proprietary xPloration® platform, an innovative high-throughput single B-cell screening technology.
The appointment marks an important milestone for OmniAb as it continues to strengthen its leadership team while pursuing new opportunities beyond its established antibody discovery licensing business. In his new position, Nwachuku will oversee the strategy, operations, and commercial growth of the xPloration platform, helping position the technology as a key driver of the company’s future expansion.
Strengthening Leadership to Support Long-Term Growth
OmniAb has built its reputation by providing pharmaceutical and biotechnology companies with cutting-edge antibody discovery technologies that enable the identification of novel therapeutic candidates. Its technology platforms are widely used by partners developing treatments across oncology, immunology, infectious diseases, and other therapeutic areas.
While the company’s antibody discovery licensing business continues to generate milestone payments and royalty opportunities through an expanding portfolio of partner programs, OmniAb is increasingly investing in complementary technologies capable of creating additional revenue streams.
The creation of the Chief Operating Officer position reflects this broader strategic vision. By appointing an experienced executive with extensive commercial and operational expertise, OmniAb aims to accelerate adoption of xPloration while ensuring the platform reaches a wider customer base across the life sciences industry.
A Proven Industry Leader Joins OmniAb
Amechi Nwachuku brings more than 25 years of leadership experience spanning life sciences, diagnostics, laboratory technologies, and global commercial operations.
Throughout his career, he has led large international organizations responsible for multi-billion-dollar businesses, overseeing commercial strategy, marketing, sales, customer engagement, and integrated operational excellence.
Most recently, Nwachuku served as Vice President of Global Commercial Genetic Sciences at Thermo Fisher Scientific, one of the world’s largest providers of scientific instruments, laboratory technologies, and diagnostic solutions. In that role, he directed worldwide commercial activities supporting advanced genetic analysis technologies used by researchers, healthcare organizations, and pharmaceutical companies.
Prior to joining Thermo Fisher Scientific, he served as Senior Vice President of Global Commercial at SCIEX, a Danaher operating company recognized globally for analytical instrumentation and mass spectrometry technologies. During his tenure, he helped drive commercial growth and strengthen customer relationships across international markets.
Earlier leadership positions included senior executive roles within Beckman Coulter Diagnostics, another Danaher company specializing in clinical diagnostics and laboratory automation. His responsibilities covered commercial operations, business development, and strategic growth initiatives across multiple regions.
Before entering the diagnostics sector, Nwachuku held international leadership positions at Johnson & Johnson Diabetes Care and Bayer, where he gained extensive experience managing global healthcare businesses and commercial organizations.
He also began his professional career as a management consultant at McKinsey & Company, advising organizations on corporate strategy, operational improvements, and business transformation.
His educational background includes a Bachelor of Science degree in Chemical Engineering as well as a Master of Business Administration from the Massachusetts Institute of Technology (MIT), combining technical expertise with strategic business leadership.
Leading the Expansion of the xPloration Platform
As Executive Vice President and Chief Operating Officer, Nwachuku’s primary responsibility will be leading the continued development and commercialization of OmniAb’s xPloration platform.
The technology represents one of the company’s most advanced innovations in antibody discovery and single-cell analysis.
Unlike conventional screening approaches that may require extensive cell culturing or complex workflows, xPloration enables researchers to rapidly identify and analyze individual antibody-producing B cells using high-throughput technologies.
This allows scientists to generate large datasets while preserving naturally paired antibody information, accelerating the identification of promising therapeutic candidates for further development.
The platform has been designed to provide pharmaceutical companies, biotechnology organizations, and academic researchers with faster, more reliable, and scalable methods for antibody discovery.
By integrating advanced automation, high-throughput workflows, and comprehensive biological analysis, xPloration aims to shorten research timelines while improving the quality of candidate selection.
Nwachuku will oversee both strategic planning and day-to-day operational execution to maximize adoption of the platform across the global research community.
Responding to Growing Industry Demand
Demand for advanced antibody discovery technologies continues to increase as pharmaceutical companies pursue increasingly complex biologic therapies.
Monoclonal antibodies remain among the fastest-growing classes of medicines, with applications extending far beyond oncology into autoimmune disorders, infectious diseases, rare genetic conditions, neuroscience, and metabolic diseases.
As therapeutic targets become more sophisticated, researchers require screening platforms capable of identifying highly specific antibodies with improved speed and precision.
High-throughput single B-cell screening technologies have become increasingly valuable because they enable scientists to evaluate thousands of antibody-producing cells simultaneously while preserving critical biological information.
Large datasets generated through these platforms can improve candidate selection, reduce development timelines, and increase the probability of identifying antibodies with desirable therapeutic characteristics.
OmniAb believes xPloration is well positioned to address these evolving industry needs.
CEO Highlights Strategic Importance of Appointment
Matt Foehr, President and Chief Executive Officer of OmniAb, described Nwachuku as an accomplished global executive whose experience will strengthen the company’s leadership team during an important stage of growth.
According to Foehr, Nwachuku has consistently demonstrated commercial excellence throughout his career by identifying market opportunities, driving sustainable growth, and creating long-term value across complex international organizations.
He noted that ongoing conversations with pharmaceutical partners and extensive market research have reinforced OmniAb’s confidence in the commercial potential of the xPloration platform.
While the company’s antibody discovery licensing business continues to perform strongly—with a growing pipeline of milestone-generating and royalty-bearing partner programs—management believes xPloration represents an important complementary growth opportunity.
Rather than replacing the licensing business, the platform expands OmniAb’s ability to serve customers while diversifying future revenue sources.
The addition of an experienced commercial executive is expected to accelerate this strategy and strengthen execution across research, operations, and customer engagement.
Complementing an Established Licensing Business
OmniAb has built a substantial business by licensing proprietary antibody discovery technologies to pharmaceutical and biotechnology companies worldwide.
Through these collaborations, partners gain access to OmniAb’s transgenic animal platforms and antibody discovery capabilities while the company receives licensing fees, milestone payments tied to clinical progress, and potential royalties on commercialized products.
This business model has created a growing portfolio of programs spanning multiple therapeutic areas and stages of development.
The introduction and expansion of xPloration provides OmniAb with an opportunity to complement this successful licensing model by offering an additional technology platform that addresses different aspects of therapeutic discovery.
Management believes combining both businesses could enhance long-term financial performance while reducing dependence on any single revenue source.
Nwachuku Sees Significant Opportunity
Commenting on his appointment, Nwachuku expressed enthusiasm about joining OmniAb during a period of technological innovation and commercial expansion.
He noted that his appreciation for the xPloration platform grew as he learned more about its scientific capabilities, differentiated technology, and potential impact on antibody discovery.
According to Nwachuku, the platform addresses a growing need within the life sciences industry for reliable, user-friendly, and high-throughput screening systems capable of generating large, information-rich datasets.
He emphasized that researchers increasingly require technologies that combine speed, scalability, and analytical precision to accelerate therapeutic discovery while improving confidence in experimental results.
Nwachuku also praised OmniAb’s scientific team and innovation-driven culture, stating that he looks forward to helping the company advance its commercial strategy and broaden the platform’s global adoption.
Supporting Next-Generation Therapeutic Discovery
The appointment comes at a time when antibody therapeutics continue to represent one of the most active areas of pharmaceutical innovation.
Advances in artificial intelligence, genomics, automation, and single-cell biology are transforming how therapeutic antibodies are identified, optimized, and developed.
Technologies capable of rapidly screening millions of immune cells while preserving natural antibody diversity are becoming increasingly important for discovering treatments targeting previously inaccessible diseases.
OmniAb’s investment in xPloration reflects broader industry trends toward integrating high-throughput analytical technologies with advanced computational approaches to accelerate drug discovery.
By strengthening leadership around this platform, the company aims to expand its role in enabling the development of future biologic medicines.
Positioning for Future Expansion
With Nwachuku joining the executive leadership team, OmniAb is positioning itself to capitalize on both its established antibody discovery licensing business and the growing commercial opportunity presented by xPloration.
His extensive experience leading global commercial organizations, implementing operational strategies, and scaling technology businesses is expected to support the company’s next phase of growth.
As pharmaceutical companies continue investing heavily in biologics and precision medicine, demand for innovative antibody discovery technologies is expected to remain strong.
Through continued investment in scientific innovation, commercial execution, and strategic leadership, OmniAb aims to strengthen its position as a leading provider of technologies that help researchers discover and develop the next generation of therapeutic antibodies for patients worldwide.
About xPloration®
xPloration represents a significant advancement in single B-cell screening and antibody discovery, designed to bolster antibody discovery output for partner campaigns using the entire suite of OmniAb transgenic animals and optimize antibody discovery efficiency through new types of functional screening assays and large-scale mining of repertoires. OmniAb’s AI-powered xPloration utilizes a through-hole format that enables the examination of millions of antibody secreting cells and a proprietary laser recovery method support the quick recovery of thousands of sequences.
For more information, please visit www.omniab.com/technology/xploration/ or www.xploration.com/.
About OmniAb®
OmniAb licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts.
At the heart of the OmniAb platform is what we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry.
Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B-cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics.
We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.